GlassScriptPhysician profile
Samuel Sungwon Kim
NPI 1023310687
$6,569.01
in general payments reported to CMS, 2019-2025
39 companies · $2,868 in 2025
The $2,868 reported for 2025 was more than what 99% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.19 · 2020: $164 · 2021: $121 · 2022: $74.85 · 2023: $1,284 · 2024: $2,045 · 2025: $2,868.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,137 · Consulting Fee: $59.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,136.77 |
| Consulting Fee | $59.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,573.79 | 2023-2025 | Dupixent |
| Grifols USA, LLC | $1,055.60 | 2023-2025 | Xembify, Gamunex-C |
| Glaxosmithkline, LLC. | $461.55 | 2020-2025 | Nucala, Rotarix, Bexsero |
| Merck Sharp & Dohme LLC | $428.16 | 2020-2025 | Vaxneuvance, Gardasil 9, Rotateq |
| Takeda Pharmaceuticals U.S.A., INC. | $290.63 | 2023-2025 | Takhzyro, Cuvitru |
| Galderma Laboratories, L.P. | $259.32 | 2025 | Nemluvio |
| Pfizer INC. | $227.21 | 2022-2025 | |
| Alk-Abello, INC | $223.96 | 2023-2025 | Grastek, Odactra, Ragwitek |
| Ars Pharmaceuticals Operations, INC. | $200.80 | 2025 | Neffy |
| Cranial Technologies, INC | $195.89 | 2020-2025 | Doc Band |
| Sanofi Pasteur INC. | $195.40 | 2024-2025 | |
| Corium, LLC | $127.35 | 2025 | Azstarys |
| Hikma Pharmaceuticals USA | $116.41 | 2023-2025 | Ryaltris, Kloxxado |
| Novartis Pharmaceuticals Corporation | $108.35 | 2023-2025 | |
| Novo Nordisk INC | $103.40 | 2024 | Wegovy |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $83.77 | 2024-2025 | Actimmune, Otezla, Repatha |
| Optinose US, INC. | $77.74 | 2024-2025 | |
| Octapharma USA, INC. | $76.26 | 2025 | Cutaquig |
| Blueprint Medicines Corporation | $74.65 | 2024 | Ayvakit |
| Incyte Corporation | $69.90 | 2024-2025 | Opzelura |
| Genentech USA, INC. | $69.70 | 2020-2024 | Xolair |
| Ionis Pharmaceuticals, INC. | $62.05 | 2025 | Dawnzera |
| Adma Biomanufacturing LLC | $59.80 | 2025 | |
| Lilly USA, LLC | $54.55 | 2025 | Ebglyss, Taltz |
| Sanofi-Aventis U.S. LLC | $48.79 | 2024-2025 | |
| Tersera Therapeutics LLC | $35.74 | 2025 | Quzyttir |
| Neos Therapeutics, LP | $32.02 | 2025 | Adzenys Xr-Odt |
| Csl Behring | $31.76 | 2024 | Hizentra |
| Pharming Healthcare, INC. | $25.69 | 2023 | Ruconest |
| Verrica Pharmaceuticals INC. | $24.62 | 2024 | Ycanth |
| Astrazeneca Pharmaceuticals LP | $24.03 | 2024 | Tezspire |
| Ge Healthcare | $23.81 | 2025 | |
| Abbvie INC. | $21.19 | 2024 | |
| Aytu Biopharma, INC. | $19.51 | 2025 | |
| Phadia US INC. | $19.50 | 2023 | Immunocap |
| Kaleo, INC. | $18.18 | 2020 | |
| Seqirus USA INC | $17.55 | 2025 | Flucelvax |
| Kowa Pharmaceuticals America, INC. | $17.19 | 2025 | Zoryve |
| Vertical Pharmaceuticals, LLC | $13.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.